100+ Free BCCP Practice Questions

Pass your Board Certified Cardiology Pharmacist exam on the first try — instant access, no signup required.

✓ No registration✓ No credit card✓ No hidden fees✓ Start practicing immediately

~65% Pass Rate

100+ Questions

100% Free

1 / 100

Question 1

Score: 0/0

Which of the following is a core component of the HFrEF 4-pillar guideline-directed medical therapy in the 2022 AHA/ACC/HFSA update?

Digoxin

SGLT2 inhibitor

Calcium channel blocker

Alpha blocker

to track

2026 Statistics

Key Facts: BCCP Exam

175

Total Questions

150 scored

4h 30m

Exam Time

BPS BCCP format

Passing Score

BPS scaled

$600

Exam Fee

BPS 2026

7 years

Certification Valid

Recertification cycle

PGY2

Residency Pathway

Cardiology pharmacy

The BCCP exam is offered by the Board of Pharmacy Specialties (BPS) and uses a scaled passing score of 75. Candidates answer 175 multiple-choice items over 4.5 hours covering cardiology-focused pharmacotherapy (ACS, HFrEF/HFpEF 4-pillar therapy, DOAC management, PCSK9/bempedoic acid lipid therapy, AF rhythm/rate control, PAD, HCM with mavacamten, pulmonary hypertension, and pharmacogenomics). Eligibility requires a PharmD plus 4 years cardiology practice (>=50% in cardiology) OR PGY1 + 2 years practice OR PGY1 + PGY2 cardiology residency. The credential is valid for 7 years and recertification is achieved through exam or BPS-approved continuing education.

Sample BCCP Practice Questions

Try these sample questions to test your BCCP exam readiness. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1Which of the following is a core component of the HFrEF 4-pillar guideline-directed medical therapy in the 2022 AHA/ACC/HFSA update?

A.Digoxin

B.SGLT2 inhibitor

C.Calcium channel blocker

D.Alpha blocker

Explanation: The 2022 AHA/ACC/HFSA heart failure guideline endorses the four foundational HFrEF pillars: ARNI (or ACEi/ARB), evidence-based beta-blocker, MRA, and SGLT2 inhibitor. SGLT2 inhibitors (dapagliflozin, empagliflozin) reduce cardiovascular death and HF hospitalization independent of diabetes status.

2According to the 2017 ACC/AHA hypertension guideline, Stage 1 hypertension begins at which blood pressure threshold?

A.SBP >=120 or DBP >=80 mm Hg

B.SBP >=130 or DBP >=80 mm Hg

C.SBP >=140 or DBP >=90 mm Hg

D.SBP >=150 or DBP >=90 mm Hg

Explanation: The 2017 ACC/AHA guideline defines Stage 1 hypertension as SBP 130-139 mm Hg or DBP 80-89 mm Hg. This lowered threshold was based on SPRINT and other evidence showing benefit of earlier intervention in high-risk patients.

3Which antiplatelet agent should be AVOIDED in patients >=75 years of age or with prior stroke/TIA according to the 2023 ACC/AHA ACS guidance?

A.Clopidogrel

B.Ticagrelor

C.Prasugrel

D.Aspirin

Explanation: Prasugrel is contraindicated in patients with a history of stroke or TIA and should generally be avoided in those >=75 years or weighing <60 kg due to excess bleeding risk demonstrated in TRITON-TIMI 38. Ticagrelor or clopidogrel are preferred in these groups.

4Which DOAC has an FDA-approved specific reversal agent named idarucizumab?

A.Apixaban

B.Rivaroxaban

C.Dabigatran

D.Edoxaban

Explanation: Idarucizumab is a humanized monoclonal antibody fragment that binds dabigatran with very high affinity to reverse its anticoagulant effect. It is indicated for life-threatening bleeding or urgent surgery in patients on dabigatran.

5According to the 2018 ACC/AHA cholesterol guideline and 2022 ECDP, what is the LDL-C threshold for considering PCSK9 inhibitor therapy in very high-risk ASCVD patients?

A.LDL-C >=40 mg/dL

B.LDL-C >=55 mg/dL

C.LDL-C >=70 mg/dL

D.LDL-C >=100 mg/dL

Explanation: In very high-risk ASCVD patients on maximally tolerated statin + ezetimibe, a PCSK9 inhibitor (alirocumab or evolocumab) may be added if LDL-C remains >=55 mg/dL (or non-HDL-C >=85 mg/dL). The 2022 ECDP explicitly supports a <55 mg/dL LDL-C target in very high-risk patients.

6Which beta-blocker is most commonly associated with CYP2D6-mediated variability and can have exaggerated effects in poor metabolizers?

A.Carvedilol

B.Metoprolol

C.Atenolol

D.Bisoprolol

Explanation: Metoprolol undergoes extensive CYP2D6 metabolism. Poor metabolizers have higher plasma concentrations and more pronounced beta-blockade. CPIC provides guidance on dose adjustment or alternative selection based on CYP2D6 phenotype.

7Which oral antiarrhythmic drug is associated with pulmonary, thyroid, and hepatic toxicity requiring routine monitoring?

A.Sotalol

B.Flecainide

C.Amiodarone

D.Dronedarone

Explanation: Amiodarone has broad multi-organ toxicity including pulmonary fibrosis, thyroid dysfunction (hyper- or hypothyroidism), hepatotoxicity, corneal deposits, and photosensitivity. Baseline TSH, LFTs, PFTs, ophthalmology exam, and CXR plus periodic monitoring are required.

8Which class of antihypertensives is contraindicated in pregnancy due to fetal renal toxicity?

A.Labetalol

B.Methyldopa

C.Nifedipine extended release

D.ACE inhibitors

Explanation: ACE inhibitors (and ARBs, direct renin inhibitors, and MRAs like spironolactone) are contraindicated in all trimesters of pregnancy due to fetal renal dysgenesis, oligohydramnios, and neonatal death. Labetalol, methyldopa, and nifedipine are preferred.

9What is the mechanism of action of sacubitril/valsartan (ARNI)?

A.Neprilysin inhibition + angiotensin II receptor blockade

B.ACE inhibition + beta-blockade

C.Aldosterone receptor antagonism

D.Direct renin inhibition

Explanation: Sacubitril is a prodrug that inhibits neprilysin (increasing natriuretic peptides), while valsartan blocks the AT1 receptor. Combined, ARNI improves morbidity and mortality in HFrEF (PARADIGM-HF) and is first-line over ACEi/ARB when feasible.

10Which of the following SGLT2 inhibitors is FDA-approved for reducing cardiovascular death and hospitalization for heart failure in adults regardless of ejection fraction?

A.Dapagliflozin

B.Canagliflozin

C.Ertugliflozin

D.Bexagliflozin

Explanation: Dapagliflozin (DELIVER, DAPA-HF) and empagliflozin (EMPEROR-Preserved, EMPEROR-Reduced) are approved for HF regardless of ejection fraction. Canagliflozin and ertugliflozin have primarily diabetes/CKD indications.

About the BCCP Exam

The BCCP (Board Certified Cardiology Pharmacist) credential recognizes pharmacists with advanced expertise in cardiovascular pharmacotherapy. The BPS exam is 175 multiple-choice questions (150 scored + 25 unscored) delivered over 4 hours 30 minutes. Content spans ACS, heart failure, hypertension, dyslipidemia, arrhythmias, anticoagulation, valvular disease, and specialized cardiology populations.

Questions

175 scored questions

Time Limit

4 hours 30 minutes

Passing Score

Scaled score 75 (BPS standard)

Exam Fee

$600 (Board of Pharmacy Specialties (BPS))

BCCP Exam Content Outline

60%

Patient Care (Cardiology-Focused)

ACS, chronic coronary disease, HFrEF/HFpEF pharmacotherapy, hypertension, dyslipidemia, atrial fibrillation, VTE, valvular heart disease, PAD, pulmonary hypertension, HCM, arrhythmias, cardiac arrest, pregnancy-cardiology, HCM, orthostatic hypotension, POTS, and pericarditis.

25%

Therapeutics and Patient Management

Anticoagulation management including DOAC selection/reversal, pharmacogenomic-guided therapy (CYP2C19, SLCO1B1), therapeutic drug monitoring, DAPT de-escalation, renal dose adjustment, and transitions of care.

15%

Professional Practice

Guideline appraisal (2022/2023 ACC/AHA/HFSA/ACCP/HRS), evidence-based medicine, cardiovascular outcomes trials interpretation, pharmacoeconomics, medication safety, and interdisciplinary team collaboration.

How to Pass the BCCP Exam

What You Need to Know

Passing score: Scaled score 75 (BPS standard)
Exam length: 175 questions
Time limit: 4 hours 30 minutes
Exam fee: $600

Keys to Passing

Complete 500+ practice questions
Score 80%+ consistently before scheduling
Focus on highest-weighted sections
Use our AI tutor for tough concepts

BCCP Study Tips from Top Performers

1Master the 4-pillar HFrEF regimen (ARNI/ACEi/ARB + beta-blocker + MRA + SGLT2i) and 2022 AHA/ACC/HFSA sequencing

2Know DOAC dosing in renal impairment, reversal (idarucizumab, andexanet alfa), and peri-procedural bridging (ASH 2018)

3Study P2Y12 selection (prasugrel avoid if >=75 yo or prior stroke; ticagrelor dyspnea) and DAPT de-escalation trials (TWILIGHT, TALOS-AMI)

4Memorize cardiology pharmacogenomics: CYP2C19 (clopidogrel), SLCO1B1 (simvastatin), CYP2D6 (metoprolol)

5Read summaries of key 2020-2025 cardiology trials: COMPASS, VICTORIA, EMPEROR-Preserved, DELIVER, EAST-AFNET 4, EXPLORER-HCM, VALOR-HCM, CLEAR Outcomes, RHAPSODY

Frequently Asked Questions

What is the BCCP exam and who administers it?

The BCCP (Board Certified Cardiology Pharmacist) exam is administered by the Board of Pharmacy Specialties (BPS), the leading global pharmacy credentialing body. It validates advanced expertise in cardiology pharmacotherapy for pharmacists who want to demonstrate specialty-level competency. The exam is delivered at Pearson VUE test centers.

What are the BCCP eligibility requirements for 2026?

BPS offers three eligibility pathways for BCCP: (1) PharmD plus four years of cardiology pharmacy practice with >=50% of responsibilities in cardiology; (2) PharmD plus completion of ASHP-accredited PGY1 residency plus two years of cardiology practice; or (3) PharmD plus PGY1 residency plus PGY2 cardiology pharmacy residency. All candidates must hold an active pharmacist license.

How many questions are on the BCCP exam and how long is it?

The BCCP exam contains 175 multiple-choice questions (150 scored plus 25 unscored pretest items) and candidates receive 4 hours 30 minutes of testing time. BPS uses scaled scoring with a passing score of 75 on the standardized scale, which accounts for form-level difficulty differences between testing windows.

How much does the BCCP exam cost?

The BCCP exam fee is $600 for first-time applicants and $300 for retake applicants in 2026. This covers BPS application processing and the Pearson VUE exam seat. Candidates should also budget for BPS-approved review courses, practice banks, and ACCP cardiology PSAP modules.

How long is BCCP certification valid and how do I recertify?

BCCP certification is valid for 7 years. Recertification can be achieved by either retaking the BCCP exam or completing BPS-approved continuing education (typically 100 hours of accredited professional development activities during the 7-year cycle). Recertification fees and CE requirements are published annually on the BPS website.

What topics are highest yield for the BCCP exam?

High-yield BCCP topics align to contemporary guidelines: 2023 ACC/AHA chronic coronary disease and ACS (DAPT, P2Y12 selection), 2022 AHA/ACC/HFSA heart failure (4-pillar HFrEF therapy with ARNI/beta-blocker/MRA/SGLT2i, vericiguat), 2023 AHA/ACC AF (CHA2DS2-VA, DOAC selection, rhythm control per EAST-AFNET 4), 2018/2022 lipid guidelines (PCSK9, bempedoic acid, inclisiran), HCM with mavacamten, and cardiology pharmacogenomics (CYP2C19/clopidogrel, SLCO1B1/statin).

How does BCCP differ from BCPS for cardiology-focused pharmacists?

BCPS is a broad pharmacotherapy certification covering many disease states, while BCCP is a cardiology-only subspecialty credential. BCCP questions are almost entirely cardiovascular and demand deeper evidence-based knowledge of cardiology trials (COMPASS, EAST-AFNET 4, VICTORIA, CLEAR Outcomes, EXPLORER-HCM). Many cardiology pharmacists hold both credentials, but BCCP is increasingly the preferred standalone credential for dedicated cardiology practice.